BioCentury
ARTICLE | Company News

Genticel, Genkyotex deal

December 30, 2016 9:07 PM UTC

The companies will merge to form a publicly traded entity that plans to develop Genkyotex's pipeline of NADPH oxidase inhibitors to treat fibrotic diseases. Genkyotex’s shareholders will receive about 11.8 Genticel shares for each Genkyotex share and hold 80% of the combined company. The deal is subject to Genticel shareholders' approval in February...